nonsequetor
7 년 전
***NEWS OUT***
http://ih.advfn.com/p.php?pid=nmona&article=75174311&symbol=PRGO
Perrigo Launches The Generic Version Of Axiron® Topical Solution
DUBLIN, July 5, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the prescription pharmaceutical launch of testosterone topical solution, 30 mg/1.5 mL (CIII), the generic equivalent to Eli Lilly and Company's Axiron® Topical Solution, 30 mg/1.5 mL (CIII).
Axiron® Topical Solution, 30 mg/1.5 mL (testosterone topical solution, 30 mg/1.5 mL) is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Annual market sales for the 12 months ending April 2017 were approximately $248 million.
Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, "This is our third new product launch in the last two weeks. These new product launches illustrate our continued focus on developing and bringing to market important treatments in prescription extended topical therapeutic categories. The Rx team remains committed to investing in complex topical products and to launching more than five new products by the end of 2017."
About Perrigo
Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is the world's largest manufacturer of over-the-counter ("OTC") healthcare products and supplier of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of "extended topical" prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China. Visit Perrigo online at (http://www.perrigo.com).
Forward-Looking Statements
Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the timing, amount and cost of any share repurchases; future impairment charges; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; potential third-party claims and litigation, including litigation relating to our restatement of previously-filed financial information; potential impacts of ongoing or future government investigations and regulatory initiatives; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions, and our ability to realize the desired benefits thereof; our ability to achieve our guidance; our ability to execute and achieve the desired benefits of announced cost-reduction efforts and other initiatives; and the timing and expense to complete the announced tender offer for certain of our outstanding notes. In addition, the Company may identify and be unable to remediate one or more material weaknesses in its internal control over financial reporting. Furthermore, the Company and/or its subsidiaries may incur additional tax liabilities in respect of 2016 and prior years as a result of any restatement or may be found to have breached certain provisions of Irish company legislation in respect of prior financial statements and if so may incur additional expenses and penalties. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2016, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
VanWilder
8 년 전
PRGO - Reckitt Benckiser Buyout Potential
Pretty quiet here for a company that may get bought anytime....literally any Day. The puzzle pieces are fitting together way too well to be just a coincidence.
Timeline:
Back in 2015 Mylan tried to go hostile for Perrigo at a $180+ price tag, but did not succeed.
June of 2016 - Rumor hits the street of a Mystery UK buyer for PRGO at the $20B level.
July of 2016 - Rumor hits again that the UK buyer is Reckitt Benckiser of the UK, and preparing a $20B offer.
September 11th 2016 - Activist Starboard Value LP takes a 4.6% stake in PRGO, Advocating several actions within the company to Unlock Shareholder value.
Reckitt Benckiser has publicly looked at buying both Merek's Consumer health division, and Pfizer's Consumer division, but both of these are now off the table. Merek's sold to Bayer, and Pfizer is not breaking up the company until at least 2018. The Pfizer news just came out 6-days ago, so until then BR may have been waiting to see if that was a Viable option. Now it is not. There are far Fewer matches for RB now, than were possibly on the Table in 2014-2015. The clock is ticking for RB to make a move, and I think that they may make a bid for Perrigo before the new year.
My guess is RB has been kicking the Tires on Perrgio now for several months (since at least June), and waiting to see where the Dust settled on the Pfizer Breakup. RB was also mentioned as a buyer for Church & Dwight this Mayy, but those Rumors were Denied by Church & Dwight.
The last Rumor in June of this year even stated the financial Firms advising both PRGO and RB. This Seems awfully specific for an unfounded Rumor, and the June Rumor actually supports the RB theory, and the July story as well. Both Reckitt and Perrigo did NOT deny these Rumors.
Last month, a report claimed Perrigo was close to an agreement to be bought by a UK-based company for $US20bn, although it did not name the latter.
The report in StreetInsider.com cited a source as saying Morgan Stanley (NYSE:MS) was advising Perrigo and Barclays PLC (LON:BARC) was among institutions advising the UK company.
Reckitt Benckiser has been on the Acquisition hunt since at least 2014 to expand their Consumer Health division. They have not Purchased anything yet that fulfills that Goal.
RB CEO:
RB’s net debt ratio of 0.7 times adjusted earnings before interest, tax, depreciation and amortization is below that of competitors Unilever at 1.1 and Procter & Gamble Co. at 1.3, meaning the company has financial flexibility to pursue transformational acquisitions. Discussing firepower, Kapoor said that RB is not thinking about limitations on the size of a potential deal.
“If any of the interesting consumer-health assets were to come up today, I believe RB has the capacity to do it. Any of them,” he said.
With PRGO stock trading at $93 from a High of $200, with a shareholder base that is Angry regarding the slump in Stock Value, Perrigo is Ripe for a takeover bid in the $135-$160 range. The Rumor articles state that Perrigo is looking for a minimum of a 100% premium, but I don't believe if RB or another acquirer made their offer Public, it would take that elevated Premium to get it accomplished. With Starboard coming on board in the past 3-weeks, the Board and newer CEO will be under tremendous pressure to get the Share Price UP, and seriously consider any/all Major moves that may be good for the Stock Price.
Option Volume has been slightly unusual 3 days the past week, with Call Volume above normal, and directionally Bullish Action.
I continue to Add the Nov and Jan PRGO call options, along with the PRGO common stock which is Cheap whether the Perrigo Buyout with Reckitt occurs or not.
LONG PRGO !!!!!!!!!
Links:
http://www.fiercepharma.com/pharma/perrigo-up-for-20b-sale-to-mystery-u-k-buyer-report
http://www.proactiveinvestors.com/companies/news/128264/reckitt-benckiser-set-to-bid-for-perrigo-rumours-128264.html
http://www.modernhealthcare.com/article/20160926/NEWS/160929928
http://www.bloomberg.com/news/articles/2015-12-04/reckitt-benckiser-ceo-would-look-at-buying-pfizer-consumer-unit
http://www.fiercepharma.com/m-a/reckitt-benckiser-gives-up-on-merck-otc-deal-leaving-bayer-open-shot
http://www.cnbc.com/2016/05/19/church-dwight-shares-spike-amid-report-of-reckitt-benckiser-takeover-bid.html
http://thefly.com/news.php?symbol=PRGO
http://247wallst.com/healthcare-business/2015/06/01/3-specialty-pharma-stocks-that-could-be-acquired-in-2015/
Hot Features
프리미엄
실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
52wkhi
4 년 전
T695
8 년 전
ClarkKant
9 년 전
DewDiligence
9 년 전
